Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Pharmaxis Ltd ( (AU:SNT) ) has issued an update.
Syntara Limited announced an investor webinar to discuss its quarterly update and Appendix 4C. The company is advancing its lead candidate, SNT-5505, for myelofibrosis and is preparing for further studies in myelodysplastic syndrome. Syntara is also working on other drug candidates targeting fibrotic and inflammatory diseases, and has collaborations for scar prevention and neurodegenerative disease treatments. This announcement highlights Syntara’s ongoing efforts in drug development and its potential impact on treating various serious health conditions.
More about Pharmaxis Ltd
Syntara Limited is a clinical stage drug development company specializing in targeting extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, SNT-5505, is aimed at treating myelofibrosis and has received FDA Orphan Drug Designation. The company is also involved in developing treatments for neurodegenerative diseases and various fibrotic and inflammatory diseases. Syntara is listed on the Australian Securities Exchange and is based in Sydney, Australia.
YTD Price Performance: -38.75%
Average Trading Volume: 3,589,326
Technical Sentiment Signal: Buy
Current Market Cap: A$79.58M
Learn more about SNT stock on TipRanks’ Stock Analysis page.